ストックスクリーナーアプリを入手
6.00
1.18%
0.07
前日終値:
$5.93
開ける：
$5.89
24時間の取引高:
866.46K
Relative Volume:
0.64
時価総額：
$343.10M
収益：
$5.82M
当期純損益:
$71.18M
株価収益率:
6.0168
EPS:
0.9972
ネットキャッシュフロー:
$-84.30M
1週間 パフォーマンス:
+1.35%
1か月 パフォーマンス:
-12.02%
6か月 パフォーマンス:
+20.72%
1年 パフォーマンス:
-12.54%
1日の値動き範囲:
$5.85
$6.02
1週間の範囲:
$5.78
$6.10
52週間の値動き範囲:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
名前
Abeona Therapeutics Inc
セクター
電話
646-813-4701
住所
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.00 | 340.82M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-03-05 | 開始されました | Oppenheimer | Outperform |
| 2024-07-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-30 | 開始されました | Stifel | Buy |
| 2020-11-11 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-02-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-10 | 再開されました | Cantor Fitzgerald | Neutral |
| 2019-08-15 | ダウングレード | Maxim Group | Buy → Hold |
| 2019-08-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-06-27 | 開始されました | Mizuho | Buy |
| 2018-10-12 | 開始されました | Mizuho | Buy |
| 2018-06-05 | 開始されました | Seaport Global Securities | Buy |
| 2017-11-08 | 開始されました | SunTrust | Buy |
| 2017-10-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-10-10 | 開始されました | Citigroup | Buy |
| 2017-10-05 | 繰り返されました | Maxim Group | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-07-18 | 繰り返されました | Maxim Group | Buy |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2017-01-06 | 開始されました | Jefferies | Buy |
| 2016-09-29 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Abeona Therapeutics Inc (ABEO) 最新ニュース
High Insider Ownership Growth Stocks To Watch In August 2026 - simplywall.st
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone - Yahoo Finance
Abeona (ABEO) Latest Quarter: EPS Misses Its Estimate in the Latest Session; Market Reaction: The Market Price Declines 2.77% for the Current SessionRevenue Growth Outlook - vinanet.vn
Abeona (ABEO) Q2 2026 Earnings Call Transcript - AOL.com
ABEO: Zevaskyn Launch Gains Momentum - Smartkarma
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlight - GuruFocus
Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty - GuruFocus
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ... - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Understanding the Setup: (ABEO) and Scalable Risk - Stock Traders Daily
Abeona Therapeutics Insiders Sell US$2.9m Of Stock, Possibly Signalling Caution - Moomoo
Abeona Therapeutics Stock Price Forecast. Should You Buy ABEO? - StockInvest.us
Montanova Capital (ABEO) reports 0.9% beneficial stake in Abeona Therapeutics - Stock Titan
ABEO Maintained by Oppenheimer -- Price Target Lowered to $21.00 - GuruFocus
Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating - marketscreener.com
Abeona Therapeutics (ABEO) Q2 2026 Earnings Call: ZEVASKYN Revenue Rises 31% - TradingKey
Abeona Therapeutics (ABEO) Stock Faces Early Launch Strain Despite Revenue Traction - Sahm
Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Abeona Therapeutics Shares Fall After Q2 Miss - marketscreener.com
Abeona Therapeutics (ABEO) Advances ZEVASKYN Rollout Amid Mixed Valuation Signals - GuruFocus
Transcript : Abeona Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Abeona Therapeutics Q2 Results: Revenue Rises 31% QoQ To $11.4 Million - scanx.trade
Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa - GuruFocus
Abeona Therapeutics Down Nearly 15%, On Pace For Largest Percent Decrease Since April 2024 -- Data Talk - Moomoo
Abeona Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Abeona Therapeutics Q2 Earnings Call Highlights - MarketBeat
Abeona stock drops after Q2 revenue miss (ABEO:NASDAQ) - Seeking Alpha
Earnings call transcript: Abeona Therapeutics misses Q2 2026 revenue view as shares fall - Investing.com
Abeona Therapeutics Reports Q2 2026 Results in Form 10-Q Filing - Kalkine Media
Abeona Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why is Abeona Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Q2 Earnings Highlight Challenges Amid Soaring Price-to-Sales Ratio - GuruFocus
Is Abeona Therapeutics Inc (ABEO) Facing Sustainability Challeng - GuruFocus
Abeona Therapeutics: Q2 Earnings Snapshot - AOL.com
ABEONA THERAPEUTICS INC. Q2 2026: Revenue $11.38M, EPS $(0.35) — 10-Q Summary - TradingView
Abeona Therapeutics Q2 net loss widens, misses analyst expectations - TradingView
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Abeona Q2 Revenue Rises 31% to $11.4 Million - Quiver Quantitative
Abeona Therapeutics reports Q2 2026: $11.4M product revenue, $20.2M net loss - TradingView
Abeona Therapeutics (ABEO) grows ZEVASKYN sales but records H1 2026 net loss - Stock Titan
Abeona Q2 FY26 net loss widens to $20.2 million; revenue rises 31% Q/Q to $11.4 million - Bitget
Abeona Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Weekly Recap: CMS NTAP for ZEVASKYN and Q2 2026 results call - TradingView
Abeona will stream its Q2 financial update on Aug. 13 - Stock Titan
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - GlobeNewswire
Abeona Therapeutics (ABEO) Projected to Announce Earnings on Thursday - MarketBeat
The Technical Signals Behind (ABEO) That Institutions Follow - Stock Traders Daily
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics Inc (ABEO) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):